Home » Tekmira Makes Improvements in the Potency of RNAi Delivery Platform
Tekmira Makes Improvements in the Potency of RNAi Delivery Platform
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference
(RNAi) therapeutics and proprietary delivery technology, announced Tuesday that new research published in the journal Nature Biotechnology discloses the
development of a new lipid component that provides a ten-fold improvement in the potency of the Company’s SNALP delivery platform.
Earth Times
Earth Times
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May